Kerr on Oncology

 
 
  • Multidisciplinary Cancer Teams Alive and Well Globally   Dr David Kerr discusses a survey of ASCO members practicing outside of the United States about their involvement in multidisciplinary team cancer care, and discovers that teamwork is flourishing.
  • Say No to Intensified Chemo in the Elderly   A study in patients with advanced colorectal cancer (median age, 80) found that adding irinotecan to 5-FU/leucovorin provided no benefit, prompting Dr David Kerr to assess chemo in the truly elderly.
  • Pharmacogenetic Testing for 5-FU Saves Lives and Money   Prospective screening for a genetic variant of DPD, an enzyme that catabolizes 5-FU, reduces mortality from 10% to 0% in patients with this variant and is cost-effective. Dr David Kerr is all for it.
  • Metronomic Capecitabine as mCRC Maintenance Therapy   Dr David Kerr discusses a small study that provides provocative results for using metronomic, low-dose, oral capecitabine as single-agent maintenance therapy in advanced colorectal cancer.
  • Is Capecitabine New Standard in Pre-op Rectal Cancer?   Dr David Kerr reports on a study in which oral capecitabine beat continuous-infusion 5-FU 'fairly and squarely' in tumor control of early rectal cancer, which may prove a new standard of practice.
  • Can Coffee KO Cancer's Return?   Early data suggest that coffee intake may reduce the recurrence rate of colon cancer, prompting Dr David Kerr to question whether to recommend that CRC patients have another cup (or two) of joe.
  • Oral Adjuvant CRC Therapy: How Little Is Enough?   Dr David Kerr comments on a study reporting that 6 months of oral UFT/LV for stage IIB/III colon cancer therapy is as effective as 18 months of treatment. He asks: Can we shorten treatment further?
  • Oncologists as a Force for Cancer Prevention?   Dr David Kerr suggests that oncologists combine patient care with public medicine and become a frontline force in advocating for public health and cancer prevention.
  • ESMO Award a Nod to Integrated Palliative Care   Dr David Kerr speaks with Dr Nathan Cherny, this year's recipient of the ESMO Award, about his work to win worldwide support for integrating palliative care into standard cancer care and training.
  • Sizing Up ESMO's Drug Benefit Scale   Dr David Kerr chats with Dr Nathan Cherny about the Magnitude of Clinical Benefit Scale, which provides a 1-5 numerical score to gauge the relative benefit of cancer drugs.
  • Wanted: Low-Cost Ways to Reduce Cancer Worldwide   Early detection is crucial to slow the cancer tidal wave in low-income countries, says Dr David Kerr, who asks for ideas on low-cost technologies and initiatives that could aid prevention strategies.
  • Checkpoint Inhibitor Effective in Subset of CRC Patients   Dr David Kerr reports on a study suggesting that mismatch-repair-deficient tumors may be easily 'spotted' by the immune system and effectively treated with the immune checkpoint inhibitor pembrolizumab.
  • Sizing Up ASCO's Value Tool   Dr David Kerr applauds ASCO for its Value Framework, saying the tool is a practical way for clinicians to gauge the relative benefit and cost of cancer treatments for individual patients.
  • You Should Live So Long   A new questionnaire, condensed from masses of data points from the UK Biobank, provides a rough estimate of your short-term life expectancy. Try it out, says Dr David Kerr.
  • One Drink Won't Hurt, but Women Beware   Renowned epidemiologist Peter Boyle talks to David Kerr about alcohol consumption, cancer risk, and the importance of extending life expectancy not just in years, but in healthy years.
  • Over-the-Counter Tx Proves Top Shelf in CRC   Dr David Kerr's top picks for the colorectal cancer presentations at ASCO 2015 surprisingly include two studies on vitamin D supplements and aspirin for patients diagnosed with colorectal cancer.
  • Location, Location, Location: In CRC, It Matters   Dr David Kerr reports on a study in which location of the primary tumor proved an independent prognostic factor in advanced colorectal cancer.
  • No Adjuvant Oxaliplatin for Elderly CRC Patients   Consensus guidelines offer distinct recommendations for adjuvant and palliative treatments in elderly patients with colorectal cancer, as discussed by Dr David Kerr.
  • My Lifetime Risk of Cancer Is 1 in 2   Dr David Kerr reports on a compelling epidemiologic study of lifetime risk for cancer in the United Kingdom demonstrating that for many adults, there is now a 1 in 2 chance of getting cancer.
  • CRC Survival Goes Down in Smoke   Prompted by a recent study on the effects of smoking on colorectal cancer survival, Dr David Kerr reports that he has increased his efforts to get his patients to stop smoking.